Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a major operation frequently necessitating red blood cell transfusion. Using multi-institutional data from the U.S. HIPEC Collaborative, this study sought to determine the association of perioperative allogenic blood transfusion (PABT) with perioperative outcomes after CRS/HIPEC.
This retrospective cohort study analyzed patients who underwent CRS/HIPEC for peritoneal surface malignancy between 2000 and 2017. Propensity score-matching was performed to mitigate bias. Univariate analysis was used to compare demographic, preoperative, intraoperative, and postoperative variables. Factors independently associated with PABT were identified using multivariate analysis.
The inclusion criteria were met by 1717 patients, 510 (29.7%) of whom required PABT. The mean Peritoneal Cancer Index (PCI) of our cohort was 14.8 ± 9.3. Propensity score-matching showed an independent association between PABT and postoperative risk of pleural effusion, hemorrhage, pulmonary embolism, enteric fistula formation, Clavien-Dindo grades 3 and 4 morbidity, longer hospital stay, and reoperation (all P < 0.05 in the multivariate analysis). Compared with the patients who received 1 to 5 red blood cell (RBC) units, the patients who received more than 5 units had a greater risk of renal impairment, a longer intensive care unit (ICU) stay, and more postoperative infections. Finally, PABT was an independent predictor of worse survival for patients with appendiceal and colorectal primaries.
Even low levels of PABT for patients undergoing CRS/HIPEC are independently associated with a greater risk of infectious and non-infectious postoperative complications, and this risk is increased for patients receiving more than 5 RBC units. Worse survival was independently predicted by PABT for patients with peritoneal carcinomatosis of an appendiceal or colorectal origin.
This is a preview of subscription content, access via your institution.
de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;39: 321–7. https://doi.org/10.1016/j.ctrv.2012.11.003.
Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–28. https://doi.org/10.1016/s1470-2045(04)01425-1.
Beal EW, Ahmed A, Grotz T, et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219:478–83.
Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9. https://doi.org/10.1245/aso.2003.01.018.
Mercier F, Dagbert F, Pocard M, et al. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. 2018;3:195–202. https://doi.org/10.1002/bjs5.97.
Owusu-Agyemang P, Zavala AM, Williams UU, et al. Assessing the impact of perioperative blood transfusions on the survival of adults undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal carcinomatosis. Vox Sang. 2017;112:567–77. https://doi.org/10.1111/vox.12546.
Saxena A, Valle SJ, Liauw W, Morris DL. Allogenic blood transfusion is an independent predictor of poorer perioperative outcomes and reduced long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of 936 cases. J Gastrointest Surg. 2017;21:1318–27. https://doi.org/10.1007/s11605-017-3444-8.
Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315–25. https://doi.org/10.1002/cncr.23553.
Sargant N, Roy A, Simpson S, et al. A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Transfus Med. 2016;26:118–22. https://doi.org/10.1111/tme.12301.
Abdelsattar ZM, Hendren S, Wong SL, Campbell DA, Henke P. Variation in transfusion practices and the effect on outcomes after noncardiac surgery. Ann Surg. 2015;262:1–6. https://doi.org/10.1097/sla.0000000000001264.
Vlot EA, Verwijmeren L, van de Garde, EMW, Kloppenburg GTL, van Dongen, E P A, Noordzij PG. Intraoperative red blood cell transfusion and mortality after cardiac surgery. BMC Anesthesiol. 2019;19:65–71. https://doi.org/10.1186/s12871-019-0738-2.
Qiu L, Wang DR, Zhang XY, et al. Impact of perioperative blood transfusion on immune function and prognosis in colorectal cancer patients. Transfus Apher Sci. 2016;54:235–241. https://doi.org/10.1016/j.transci.2015.07.004.
Squires MH, Kooby DA, Poultsides GA, et al. Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7-institution analysis of 765 patients from the US gastric cancer collaborative. J Am Coll Surg. 2015;221:767–77. https://doi.org/10.1016/j.jamcollsurg.2015.06.012.
Cata JP, Lasala J, Pratt G, Feng L, Shah JB. Association between perioperative blood transfusions and clinical outcomes in patients undergoing bladder cancer surgery: a systematic review and meta-analysis study. J Blood Transfus. 2016;2016:9876394. https://doi.org/10.1155/2016/9876394.
Nizri E, Kusamura S, Fallabrino G, Guaglio M, Baratti D, Deraco M. Dose-dependent effect of red blood cells transfusion on perioperative and long-term outcomes in peritoneal surface malignancies treated with cytoreduction and HIPEC. Ann Surg Oncol. 2018;25:3264–70. https://doi.org/10.1245/s10434-018-6630-3.
Tabrizian P, Shrager B, Jibara G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg. 2014;18:1024–31. https://doi.org/10.1007/s11605-014-2477-5.
Wagner PL, Austin F, Maduekwe U, et al. Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival. Ann Surg Oncol. 2013;20:1056–62. https://doi.org/10.1245/s10434-012-2791-7.
Hompes D, D’Hoore A, Van Cutsem E, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a belgian multicentre prospective phase II clinical study. Ann Surg Oncol. 2012;19:2186–94. https://doi.org/10.1245/s10434-012-2264-z.
Ihemelandu C, Mavros MN, Sugarbaker P. Adverse events postoperatively had no impact on long-term survival of patients treated with cytoreductive surgery with heated intraperitoneal chemotherapy for appendiceal cancer with peritoneal metastases. Ann Surg Oncol. 2016;23:4231–7. https://doi.org/10.1245/s10434-016-5355-4.
Pang QY, An R, Liu HL. Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis. World J Surg Oncol. 2019;17:7. https://doi.org/10.1186/s12957-018-1551-y.
Alam A, Lin Y, Lima A, Hansen M, Callum JL. The prevention of transfusion-associated circulatory overload. Transfus Med Rev. 2013;27:105–12. https://doi.org/10.1016/j.tmrv.2013.02.001.
Elmi M, Mahar A, Kagedan D, et al. The impact of blood transfusion on perioperative outcomes following gastric cancer resection: an analysis of the American College of Surgeons national surgical quality improvement program database. Can J Surg. 2016;59:322–9. https://doi.org/10.1503/cjs.004016 [pii].
Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–8. https://doi.org/10.1080/00031305.1985.10479383.
Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23. https://doi.org/10.1109/tac.1974.1100705.
Hosmer DW, Lemesbow S. Goodness-of-fit tests for the multiple logistic regression model. Commun Stat Theory Methods. 1980;9:1043–69. https://doi.org/10.1080/03610928008827941.
Nannicini T. Simulation-based sensitivity analysis for matching estimators. Stata J. 2007;7:334–50. https://doi.org/10.1177/1536867x0700700303.
Saxena A, Yan TD, Chua TC, et al. Risk factors for massive blood transfusion in cytoreductive surgery: a multivariate analysis of 243 procedures. Ann Surg Oncol. 2009;16:2195–203. https://doi.org/10.1245/s10434-009-0484-7.
Yang T, Lu JH, Lau WY, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a propensity score-matching analysis. J Hepatol. 2016;64:583–93. https://doi.org/10.1016/j.jhep.2015.10.012.
Halabi WJ, Jafari MD, Nguyen VQ, et al. Blood transfusions in colorectal cancer surgery: incidence, outcomes, and predictive factors: an American College of Surgeons national surgical quality improvement program analysis. Am J Surg. 2013;206:1024–33. https://doi.org/10.1016/j.amjsurg.2013.10.001.
Gunka I, Dostalik J, Martinek L, Gunkova P, Mazur M. Impact of blood transfusions on survival and recurrence in colorectal cancer surgery. Indian J Surg. 2013;75:94–101. https://doi.org/10.1007/s12262-012-0427-6.
Jagoditsch M, Pozgainer P, Klingler A, Tschmelitsch J. Impact of blood transfusions on recurrence and survival after rectal cancer surgery. Dis Colon Rectum. 2006;49:1116–30. https://doi.org/10.1007/s10350-006-0573-7.
Gabriel E, Elli E, Bagaria S, et al. Robotic-assisted cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). J Robot Surg. 2019;13:175–9. https://doi.org/10.1007/s11701-018-0820-7.
Esquivel J, Averbach A, Chua TC. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: feasibility, morbidity and outcome in an early experience. Ann Surg. 2011;253:764–8. https://doi.org/10.1097/sla.0b013e31820784df.
Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85:61–7. https://doi.org/10.1002/jso.20013.
Yan TD, Links M, Fransi S, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy: a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol. 2007;14:2270–80. https://doi.org/10.1245/s10434-007-9406-8.
Saxena A, Chua TC, Fransi S, Liauw W, Morris DL. Effectiveness of early and aggressive administration of fresh frozen plasma to reduce massive blood transfusion during cytoreductive surgery. J Gastrointest Oncol. 2013;4:30–9. https://doi.org/10.3978/j.issn.2078-6891.2012.046.
Miki C, Hiro J, Ojima E, Inoue Y, Mohri Y, Kusunoki M. Perioperative allogeneic blood transfusion: the related cytokine response and long-term survival after potentially curative resection of colorectal cancer. Clin Oncol R Coll Radiol. 2006;18:60–6.
Berger Y, Aycart S, Mandeli JP, Heskel M, Sarpel U, Labow DM. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: outcomes from a single tertiary center. Surg Oncol. 2015;24:264–9. https://doi.org/10.1016/j.suronc.2015.06.013.
Salti GI, Ailabouni L, Undevia S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis. Ann Surg Oncol. 2012;19:1410–15. https://doi.org/10.1245/s10434-012-2240-7.
Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol. 2014;21:1147–52. https://doi.org/10.1245/s10434-013-3443-2.
Gilani SNS, Mehta A, Garcia-Fadrique A, et al. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival. Int J Hyperthermia. 2018;34:578–84. https://doi.org/10.1080/02656736.2018.1434902.
Kumar A, Guss ZD, Courtney PT, et al. Evaluation of the use of cancer registry data for comparative effectiveness research. JAMA Netw Open. 2020;3:e2011985. https://doi.org/10.1001/jamanetworkopen.2020.11985.
Busch OR, Hop WC, Marquet RL, Jeekel J. Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg. 1994;220:791–7. https://doi.org/10.1097/00000658-199412000-00013.
Polanco PM, Ding Y, Knox JM, et al. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol. 2015;22:1673–9. https://doi.org/10.1245/s10434-014-4111-x.
There are no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Kubi, B., Nudotor, R., Fackche, N. et al. Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. Ann Surg Oncol (2021). https://doi.org/10.1245/s10434-020-09501-7